Last reviewed 2026-05-14 · How we verify

Radiolabelled GSK189075

GlaxoSmithKline · Phase 1 active Small molecule

Radiolabelled GSK189075 is a Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 1 development.

At a glance

Generic name	Radiolabelled GSK189075
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Radiolabelled GSK189075 CI brief — competitive landscape report
Radiolabelled GSK189075 updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI

Frequently asked questions about Radiolabelled GSK189075

What is Radiolabelled GSK189075?

Radiolabelled GSK189075 is a Small molecule drug developed by GlaxoSmithKline.

Who makes Radiolabelled GSK189075?

Radiolabelled GSK189075 is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What development phase is Radiolabelled GSK189075 in?

Radiolabelled GSK189075 is in Phase 1.

Manufacturer: GlaxoSmithKline — full pipeline
Compare: Radiolabelled GSK189075 vs similar drugs
Pricing: Radiolabelled GSK189075 cost, discount & access